Trending NewsTrending NewsMost-Upgraded StocksMost-UpgradedNASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $460.42 +0.14 (+0.03%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$460.04 -0.38 (-0.08%) As of 11/6/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Amgen Stock (NASDAQ:AMGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amgen alerts:Sign Up Key Stats Today's Range$447.04▼$462.9150-Day Range$375.65▼$478.4852-Week Range$312.39▼$483.99Volume2.58 million shsAverage Volume2.84 million shsMarket Capitalization$249.05 billionP/E Ratio26.71Dividend Yield2.19%Price Target$420.80Consensus RatingHold Company Overview Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.AI Generated. May Contain Errors. Read More Amgen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreAMGN MarketRank™: 4.024887800895 of 5 starsAmgen scored higher than 80% of companies evaluated by MarketBeat, and ranked 146th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 1 strong buy rating, 11 buy ratings, 18 hold ratings, and 3 sell ratings.Downside RiskAmgen has a consensus price target of $420.80, representing about 8.6% downside from its current price of $460.42.Amount of Analyst CoverageAmgen has been the subject of 26 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth7.16% Earnings GrowthEarnings for Amgen are expected to grow by 7.16% in the coming year, from $23.33 to $25.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 26.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 26.71, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.49.Price to Earnings Growth RatioAmgen has a PEG Ratio of 3.21. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 17.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.50% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.97.Change versus previous monthShort interest in Amgen has recently decreased by 4.63%, indicating that investor sentiment is improving. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldAmgen pays a meaningful dividend of 2.19%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Amgen is 58.47%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 40.32% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. News and Social Media4.2 / 5News Sentiment0.73 News SentimentAmgen has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 110 news articles for Amgen this week, compared to 9 articles on an average week.Search Interest37 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.MarketBeat Follows27 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 238% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,346,510.00 in company stock.Percentage Held by Insiders0.85% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. Receive AMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMGN Stock News HeadlinesAmgen (NASDAQ:AMGN) Price Target Raised to $464.004 hours ago | americanbankingnews.comAmgen (AMGN) Gets a Hold from GuggenheimNovember 6 at 9:14 PM | theglobeandmail.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 8 at 1:00 AM | Behind the Markets (Ad)Amgen (AMGN) Receives a Buy from ScotiabankNovember 6 at 11:11 AM | theglobeandmail.comAmgen (AMGN) Receives a Hold from Leerink PartnersNovember 6 at 11:11 AM | theglobeandmail.comAmgen Earnings Call Highlights Growth, Pipeline MomentumNovember 6 at 6:10 AM | theglobeandmail.comWhile biotech bets swing on trial data, this dividend payer gained 72% since 2024November 6 at 6:10 AM | finance.yahoo.com57 ETFs Add to Amgen (AMGN) Holdings on WednesdayNovember 6 at 6:10 AM | finance.yahoo.comSee More Headlines AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $327.31 at the start of the year. Since then, AMGN shares have increased by 40.7% and is now trading at $460.42. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, November, 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.79 by $0.66. The firm's quarterly revenue was up 8.5% compared to the same quarter last year. Read the conference call transcript. Does Amgen have any subsidiaries? Amgen subsidiaries include TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and others. Who are Amgen's major shareholders? Amgen's top institutional investors include Fisher Asset Management LLC (0.31%), Assenagon Asset Management S.A. (0.28%), Sumitomo Mitsui Trust Group Inc. (0.27%) and Mirae Asset Global Investments Co. Ltd. (0.15%). Insiders that own company stock include Murdo Gordon, David M Reese, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel and Rachna Khosla. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Pfizer (PFE), Bristol Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Record date for 9/11 Dividend8/21/2026Ex-Dividend for 9/11 Dividend8/21/2026Dividend Payable9/11/2026Last Earnings11/03/2026Today11/07/2026Record date for 12/11 Dividend11/20/2026Ex-Dividend for 12/11 Dividend11/20/2026Dividend Payable12/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 AMGN's financial health is in the Green zone, according to TradeSmith. AMGN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees31,500Year Founded1980Price Target and Rating Average Price Target for Amgen$420.80 High Price Target$536.00 Low Price Target$200.00 Potential Upside/Downside-8.6%Consensus RatingHold Rating Score (0-4)2.30 Research Coverage33 Analysts Profitability EPS (Trailing Twelve Months)$17.24 Trailing P/E Ratio26.71 Forward P/E Ratio18.42 P/E Growth3.21Net Income$7.71 billion Net Margins24.14% Pretax Margin28.41% Return on Equity114.99% Return on Assets13.47% Debt Debt-to-Equity Ratio3.60 Current Ratio1.48 Quick Ratio1.13 Sales & Book Value Annual Sales$36.75 billion Price / Sales6.78 Cash Flow$33.80 per share Price / Cash Flow13.62 Book Value$26.53 per share Price / Book17.35Miscellaneous Outstanding Shares540,910,000Free Float536,313,000Market Cap$249.05 billion OptionableOptionable Beta0.43 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:AMGN) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
